Celldex Therapeutics Limited

Medarex Inc.

Bristol-myers Squibb Compnay

Celldex Research Corporation

Celdara Medical, LLC

Mederax, Inc.

E. R. Squibb Sons, Inc.

Tibor P Keler

Yashwant M Deo

Lizhen He

Laura A Vitale

Robert F Graziano

Joel Goldstein

Alan J Korman

Lawrence J Thomas

Venky Ramakrishna

John Treml

Nils Lonberg

Edward L Halk

Michael Endres

Karuna Sundarapandiyan

Jenifer Widger

Andrea Crocker

Tom O'Neill

Henry C Marsh

Vladimir Coric

Thomas Davis

Mohan Srinivasan

Israel Lowy

Diann Blanset

Thomas Andrew Davis

Terrance A Stadheim

Joana M Murad

Jake Reder

Li-Zhen He

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Agonistic antibodies that bind human CD40 and uses thereof

This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.

Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

The invention provides chimeric antigen receptors (CARs) that specifically bind to the T-cell immunoglobulin and mucin domain 1 (TIM-1) protein. The invention further relates to modified immune cells, e.g., T or NK cells, comprising such CARs, CAR-encoding nucleic acids, CAR-encoding vectors, and methods of making such compositions. The invention further relates to methods for therapeutic use of these CARs and modified immune cells for the treatment of a condition, disorder, or disease associated with cells expressing TIM-1 (e.g., cancer).

Chimeric antigen receptors targeting TIM-1

Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.

Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs

Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Antibodies that bind human CD27 and uses thereof

Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies

Nucleic acids encoding agonistic antibodies that bind CD40

This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.

Agonistic antibodies that bind CD40

Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)

The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (&#x3b2;hCG) antigen linked to an anti-mannose receptor (MR) antibody.

Antibody vaccine conjugates and uses therefor

Growing community of inventors

Princeton, NJ, United States of America

Tibor P Keler